• Something wrong with this record ?

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

L. Sromova, P. Busek, H. Posova, J. Potockova, P. Skrha, M. Andel, A. Sedo,

. 2016 ; 118 (-) : 183-192. [pub] 20160618

Language English Country Ireland

Document type Journal Article, Observational Study

Grant support
NT12407 MZ0 CEP Register

AIM: To assess intraindividually the effects of DPP-IV inhibition on the subpopulations of immune cells in type 2 diabetes mellitus (DM2) patients during the course of treatment with sitagliptin. METHODS: In this open label non-randomized observational study with a control group DM2 patients were examined before the initiation of the DPP-IV inhibitor administration (sitagliptin 100mg once daily) and then after 4weeks and 12months. Inhibition of the blood plasma DPP-IV enzymatic activity was determined by a chromogenic assay, the immunophenotyping of the blood cell subpopulations was performed using flow cytometry and blood plasma cytokine concentrations were quantified using an array-based multiplex ELISA. All parameters were evaluated in relation to the entry values in individual patients. RESULTS: The blood plasma DPP-IV enzymatic activity was effectively inhibited during the sitagliptin treatment. A significant decrease of the proportion of Treg cells (to 86±31% (median±SD) of entry values, p=0.001) and an increase of Th1 cells (to 120±103% (median±SD) of entry values, p=0.004) were observed after 4weeks but not after one year of the sitagliptin treatment. No changes were observed in the ratio of CD4(+)/CD8(+) cells, in the quantity of NK and Th2 cells and blood plasma cytokine levels. CONCLUSIONS: Sitagliptin treatment may cause temporary changes of the proportion of lymphocyte subpopulations in patients with DM2. The consequent deregulation of the immune system should be considered as a possible cause of the eventual side effects of long term DPP-IV inhibition.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000245
003      
CZ-PrNML
005      
20190923103637.0
007      
ta
008      
170103s2016 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.diabres.2016.06.020 $2 doi
024    7_
$a 10.1016/j.diabres.2016.06.020 $2 doi
035    __
$a (PubMed)27388675
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Stollinová Šromová, Lucie $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 12853 Prague 2, Czech Republic. Electronic address: lsrom@lf1.cuni.cz. $7 xx0211880
245    14
$a The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus / $c L. Sromova, P. Busek, H. Posova, J. Potockova, P. Skrha, M. Andel, A. Sedo,
520    9_
$a AIM: To assess intraindividually the effects of DPP-IV inhibition on the subpopulations of immune cells in type 2 diabetes mellitus (DM2) patients during the course of treatment with sitagliptin. METHODS: In this open label non-randomized observational study with a control group DM2 patients were examined before the initiation of the DPP-IV inhibitor administration (sitagliptin 100mg once daily) and then after 4weeks and 12months. Inhibition of the blood plasma DPP-IV enzymatic activity was determined by a chromogenic assay, the immunophenotyping of the blood cell subpopulations was performed using flow cytometry and blood plasma cytokine concentrations were quantified using an array-based multiplex ELISA. All parameters were evaluated in relation to the entry values in individual patients. RESULTS: The blood plasma DPP-IV enzymatic activity was effectively inhibited during the sitagliptin treatment. A significant decrease of the proportion of Treg cells (to 86±31% (median±SD) of entry values, p=0.001) and an increase of Th1 cells (to 120±103% (median±SD) of entry values, p=0.004) were observed after 4weeks but not after one year of the sitagliptin treatment. No changes were observed in the ratio of CD4(+)/CD8(+) cells, in the quantity of NK and Th2 cells and blood plasma cytokine levels. CONCLUSIONS: Sitagliptin treatment may cause temporary changes of the proportion of lymphocyte subpopulations in patients with DM2. The consequent deregulation of the immune system should be considered as a possible cause of the eventual side effects of long term DPP-IV inhibition.
650    _2
$a dospělí $7 D000328
650    _2
$a diabetes mellitus 2. typu $x krev $x farmakoterapie $x imunologie $7 D003924
650    _2
$a inhibitory dipeptidylpeptidasy 4 $x aplikace a dávkování $7 D054873
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a počet lymfocytů $7 D018655
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a sitagliptin fosfát $x aplikace a dávkování $7 D000068900
650    _2
$a regulační T-lymfocyty $x účinky léků $x imunologie $7 D050378
650    _2
$a Th1 buňky $x účinky léků $x imunologie $7 D018417
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Bušek, Petr $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 12853 Prague 2, Czech Republic. Electronic address: busekpetr@seznam.cz. $7 xx0094315
700    1_
$a Posová, Helena, $u Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University in Prague, Studnickova 7, 12000 Prague 2, Czech Republic. Electronic address: hmare@lf1.cuni.cz. $d 1963- $7 xx0060265
700    1_
$a Potočková, Jana $u 2nd Department of Internal Medicine, 3rd Faculty of Medicine and Faculty Hospital Královské Vinohrady, Charles University in Prague, Srobarova 1150, 10034 Prague 10, Czech Republic. Electronic address: potocko@fnkv.cz. $7 xx0071181
700    1_
$a Škrha, Pavel $u 2nd Department of Internal Medicine, 3rd Faculty of Medicine and Faculty Hospital Královské Vinohrady, Charles University in Prague, Srobarova 1150, 10034 Prague 10, Czech Republic. Electronic address: pavel.skrha@email.cz. $7 xx0211879
700    1_
$a Anděl, Michal $u 2nd Department of Internal Medicine, 3rd Faculty of Medicine and Faculty Hospital Královské Vinohrady, Charles University in Prague, Srobarova 1150, 10034 Prague 10, Czech Republic. Electronic address: andel@fnkv.cz. $7 jn19981228006
700    1_
$a Šedo, Aleksi, $u Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, U nemocnice 5, 12853 Prague 2, Czech Republic. Electronic address: aleksi@cesnet.cz. $d 1967- $7 jn20000605245
773    0_
$w MED00001385 $t Diabetes research and clinical practice $x 1872-8227 $g Roč. 118, č. - (2016), s. 183-192
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27388675 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20190923104033 $b ABA008
999    __
$a ok $b bmc $g 1179385 $s 960812
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 118 $c - $d 183-192 $e 20160618 $i 1872-8227 $m Diabetes research and clinical practice $n Diabetes Res Clin Pract $x MED00001385
GRA    __
$a NT12407 $p MZ0
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...